National Institutes of Health (NIH)-Sponsored Consortium of Food Allergy Research (CoFAR) Starts a Phase 2 Clinical Study With DBV Technologies' Viaskin® Peanut in the Treatment of Peanut Allergy

Published: Oct 24, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, and BAGNEUX, France, Oct. 24, 2013 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new approach in the treatment of allergies, and the Consortium For Food Allergy Research (CoFAR) announced today that the CoFAR started enrolling patients into a multi-center, randomized, double-blinded, placebo-controlled trial using Viaskin® Peanut to treat children and adults with peanut allergy. The trial "Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled, Phase II study in Children and Adult" is also known as CoFAR6.

Help employers find you! Check out all the jobs and post your resume.

Back to news